Phase Ia Trial Design
The single-centre, single-arm design limits generalisability and introduces potential bias. The trial evaluates intrathecal pemetrexed with or without intrathecal bevacizumab in advanced NSCLC patients with confirmed leptomeningeal metasta…
1 sources - 6 claims
The single-centre, single-arm design limits generalisability and introduces potential bias. The trial evaluates intrathecal pemetrexed with or without intrathecal bevacizumab in advanced NSCLC patients with confirmed leptomeningeal metastases.